MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy

Abstract

Cancer therapy remains an active field of investigation, particularly in understanding and overcoming therapy resistance. Small non-coding RNAs, such as microRNAs (miRNAs), are emerging as key regulators of cancer survival, progression, proliferation, invasion, migration, and metastasis. Although many studies have linked miRNAs to cancer therapy outcomes, significant questions remain regarding their precise molecular and cellular roles in therapy resistance. Increasing evidence shows that miRNAs influence critical pathways such as apoptosis, immune evasion, and other signaling cascades. However, there have been many setbacks because of the limitations in knowledge of each specific miRNA’s function. A deeper understanding of miRNA expression and function may enhance the development of more effective cancer therapeutics and improve overall survival of patients. This review explores the role of miRNA expression as a key regulator of therapeutic resistance in cancer patients.

Keywords

Non-coding RNAs / microRNAs / cancer / therapy / drug resistance

References

[1] Siegel RL,Jemal A.Cancer statistics, 2024.CA Cancer J Clin2024;74:12-49

[2] Liu B,Tan L,Guan XY.Exploring treatment options in cancer: tumor treatment strategies.Signal Transduct Target Ther2024;9:175 PMCID:PMC11252281

[3] Kim SY,Yoon S.The roles and mechanisms of coding and noncoding RNA variations in cancer.Exp Mol Med2024;56:1909-20 PMCID:PMC11447202

[4] Esposito R,Uroda T.Author Correction: Tumour mutations in long noncoding RNAs enhance cell fitness.Nat Commun2023;14:5463 PMCID:PMC10482901

[5] Mattick JS,Carninci P.Long non-coding RNAs: definitions, functions, challenges and recommendations.Nat Rev Mol Cell Biol2023;24:430-47 PMCID:PMC10213152

[6] Zhang N,Li Y.Mechanisms and therapeutic implications of gene expression regulation by circRNA-protein interactions in cancer.Commun Biol2025;8:77 PMCID:PMC11748638

[7] Huang A,Wu Z,Huang Y.Circular RNA-protein interactions: functions, mechanisms, and identification.Theranostics2020;10:3503-17 PMCID:PMC7069073

[8] Bhaskaran M.MicroRNAs: history, biogenesis, and their evolving role in animal development and disease.Vet Pathol2014;51:759-74 PMCID:PMC4013251

[9] De-escalation Study for Stage IIa/​IIb < 3 cm Seminoma (EDEN). ClinicalTrials.gov ID: NCT05529251. 2024. Available from: https://clinicaltrials.gov/study/NCT05529251?id=NCT05529251&rank=1. [Last accessed on 9 Dec 2025]

[10] Almeida MI,Calin GA.MicroRNA history: discovery, recent applications, and next frontiers.Mutat Res2011;717:1-8

[11] Rupaimoole R.MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.Nat Rev Drug Discov2017;16:203-22

[12] Cortez MA,Valdecanas D.PDL1 regulation by p53 via miR-34.J Natl Cancer Inst2016;108:djv303 PMCID:PMC4862407

[13] Metcalf GAD.MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances.Oncogene2024;43:2135-42 PMCID:PMC11226400

[14] Tylden ES,Lukic M.Roles of miR-20a-5p in breast cancer based on the clinical and multi-omic (CAMO) cohort and in vitro studies.Sci Rep2024;14:25022 PMCID:PMC11499649

[15] Bailey S,Alonso-Crisostomo L.Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption.Br J Cancer2023;129:1451-61 PMCID:PMC10628203

[16] Aqeilan RI,Croce CM.miR-15a and miR-16-1 in cancer: discovery, function and future perspectives.Cell Death Differ2010;17:215-20

[17] Chen B,Yang C,Horst D.Targeting non-coding RNAs to overcome cancer therapy resistance.Signal Transduct Target Ther2022;7:121 PMCID:PMC9008121

[18] Shaham L,Gefen N,Izraeli S.MiR-125 in normal and malignant hematopoiesis.Leukemia2012;26:2011-8

[19] Liu J,Tang W,Mei Y.Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p.Cancer Cell Int2021;21:55 PMCID:PMC7809732

[20] Meng F,Wehbe-Janek H,Jacob ST.MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.Gastroenterology2007;133:647-58 PMCID:PMC4285346

[21] Zaug AJ,Nandakumar J.Functional interaction between telomere protein TPP1 and telomerase.Genes Dev2010;24:613-22 PMCID:PMC2841338

[22] O’Neill TA,López-Martínez J.A method for assessing the physical recovery of Antarctic desert pavements following human-induced disturbances: a case study in the Ross Sea region of Antarctica.J Environ Manage2012;112:415-28

[23] Kumar MS,Pester RE.Suppression of non-small cell lung tumor development by the let-7 microRNA family.Proc Natl Acad Sci U S A2008;105:3903-8 PMCID:PMC2268826

[24] Introini-Collison IB.Opioid peptidergic systems modulate the activity of beta-adrenergic mechanisms during memory consolidation processes.Behav Neural Biol1986;46:227-41

[25] Gao Z,Wang X.DNA damage response-related ncRNAs as regulators of therapy resistance in cancer.Front Pharmacol2024;15:1390300 PMCID:PMC11381396

[26] Li H,Li Y.DNA damage response-related signatures characterize the immune landscape and predict the prognosis of HCC via integrating single-cell and bulk RNA-sequencing.Int Immunopharmacol2024;137:112475

[27] Chen Y,Chen X.Long non-coding RNAs: from disease code to drug role.Acta Pharm Sin B2021;11:340-54 PMCID:PMC7893121

[28] Czochor JR,Glazer PM.miR-155 overexpression promotes genomic instability by reducing high-fidelity polymerase delta expression and activating error-prone DSB repair.Mol Cancer Res2016;14:363-73 PMCID:PMC5021065

[29] Chen J,Li J.miR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3.Int J Mol Med2018;41:1855-66 PMCID:PMC5810196

[30] Zhou X,Jia Z.Non-coding RNA in cancer drug resistance: underlying mechanisms and clinical applications.Front Oncol2022;12:951864

[31] Li XJ,Tang JH.MicroRNA-34a: a potential therapeutic target in human cancer.Cell Death Dis2014;5:e1327 PMCID:PMC4123066

[32] Rogers TJ,Greene LI.Reversal of triple-negative breast cancer EMT by miR-200c decreases tryptophan catabolism and a program of immunosuppression.Mol Cancer Res2019;17:30-41 PMCID:PMC6318067

[33] Juthani R,Mittra I.New light on chemotherapy toxicity and its prevention.BJC Rep2024;2:41 PMCID:PMC11524128

[34] Shi F,Liu Z,Wang T.miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2.J Cell Biochem2019;120:15018-26

[35] Cao L,Li F.MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.BMB Rep2018;51:456-61 PMCID:PMC6177509

[36] Jing X,Ding K.Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53.Clin Transl Med2022;12:e780 PMCID:PMC9076018

[37] Liang Z,Huang K,Shim H.Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN.Pharm Res2011;28:3091-100

[38] Kastl L,Schofield AC.MiRNA-34a is associated with docetaxel resistance in human breast cancer cells.Breast Cancer Res Treat2012;131:445-54

[39] Rama AR,Mesas C.Circular sponge against miR-21 enhances the antitumor activity of Doxorubicin against breast cancer cells.Int J Mol Sci2022;23:14803 PMCID:PMC9736351

[40] Torres-Ruiz S,Lameirinhas A.MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.Cell Death Discov2024;10:372 PMCID:PMC11341569

[41] Kim MW,Lee S.Exploring miRNA-target gene profiles associated with drug resistance in patients with breast cancer receiving neoadjuvant chemotherapy.Oncol Lett2024;27:158 PMCID:PMC10902752

[42] Wang Z.Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21.Oncol Lett2018;15:4585-91 PMCID:PMC5835921

[43] Brown A,Tchounwou PB.Cisplatin-based chemotherapy of human cancers.J Cancer Sci Ther2019;11:97 PMCID:PMC7059781

[44] Bao L,Mehra S,Moroz K.Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.Am J Pathol2012;180:2490-503 PMCID:PMC3378910

[45] Wei L,Armaly AM,Xu L.HuR inhibition overcomes cFLIP-mediated doxorubicin resistance in triple-negative breast cancer.NPJ Precis Oncol2024;8:286 PMCID:PMC11661992

[46] El Omari N,Elhrech H.Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma.Eur J Pharm Sci2025;208:107057

[47] Gertz M,Nguyen GT.Ex-527 inhibits Sirtuins by exploiting their unique NAD⁺-dependent deacetylation mechanism.Proc Natl Acad Sci U S A2013;110:E2772-81 PMCID:PMC3725051

[48] Itzhak Y,Weissman BA.New analgesic drugs derived from phencyclidine.J Med Chem1981;24:496-9

[49] Ceballos MP,Quiroga AD.Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines.Toxicol Lett2018;289:63-74

[50] Pujia R,Coppola A,Pujia A.The potential role of C-peptide in sexual and reproductive functions in type 1 diabetes mellitus: an update.Curr Diabetes Rev2022;18:e051021196983

[51] Pavlíková L,Breier A.The roles of microRNAs in cancer multidrug resistance.Cancers2022;14:1090 PMCID:PMC8870231

[52] Min HY.Molecular targeted therapy for anticancer treatment.Exp Mol Med2022;54:1670-94 PMCID:PMC9636149

[53] Yan H,Tang S.MiRNAs in anti-cancer drug resistance of non-small cell lung cancer: recent advances and future potential.Front Pharmacol2022;13:949566 PMCID:PMC9640411

[54] Tang W,Zhang W.The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.Signal Transduct Target Ther2020;5:87 PMCID:PMC7292831

[55] Ji L,Wan Z.miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR.Cell Death Dis2020;11:250 PMCID:PMC7170966

[56] Gao Y,Liu C.miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB.Sci Rep2019;9:18844 PMCID:PMC6906507

[57] Fattore L,Pisanu ME.Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma.Cell Death Differ2019;26:1267-82 PMCID:PMC6748102

[58] Bassot A,Haddad SA.Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma.Cell Death Dis2023;14:630 PMCID:PMC10519979

[59] Angerilli V,Businello G.MicroRNAs as predictive biomarkers of resistance to targeted therapies in gastrointestinal tumors.Biomedicines2021;9:318 PMCID:PMC8003870

[60] Magee P,Garofalo M.Role of microRNAs in chemoresistance.Ann Transl Med2015;3:332 PMCID:PMC4690999

[61] Graziano F,Loupakis F.Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.Pharmacogenomics J2010;10:458-64

[62] Pedroza-Torres A,Montaño S.Radio-miRs: a comprehensive view of radioresistance-related microRNAs.Genetics2024;227:iyae097 PMCID:PMC11304977

[63] Sgouros G,McDevitt MR.Radiopharmaceutical therapy in cancer: clinical advances and challenges.Nat Rev Drug Discov2020;19:589-608 PMCID:PMC7390460

[64] Rezaeian AH,Calin GA.Therapeutic potential of the miRNA-ATM axis in the management of tumor radioresistance.Cancer Res2020;80:139-50

[65] Zhang P,Rodriguez-Aguayo C.miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13.Nat Commun2014;5:5671 PMCID:PMC4377070

[66] Tian Y,Yi P.MiRNAs in radiotherapy resistance of nasopharyngeal carcinoma.J Cancer2020;11:3976-85 PMCID:PMC7171507

[67] Chen Y,Gong Y,Wei Y.MicroRNA: a novel implication for damage and protection against ionizing radiation.Environ Sci Pollut Res Int2021;28:15584-96 PMCID:PMC7854028

[68] Salim H,Zong D.MiRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence.Br J Cancer2012;107:1361-73 PMCID:PMC3494421

[69] Xu H,Wang D.The promising role of miRNAs in radioresistance and chemoresistance of nasopharyngeal carcinoma.Front Oncol2024;14:1299249 PMCID:PMC10933132

[70] Ahmad P,Slavik M,Smilek P.MicroRNAs involvement in radioresistance of head and neck cancer.Dis Markers2017;2017:8245345 PMCID:PMC5343268

[71] Zhang X,Lin S,Cui S.MicroRNA-216a enhances the radiosensitivity of pancreatic cancer cells by inhibiting beclin-1-mediated autophagy.Oncol Rep2015;34:1557-64

[72] Zhang Y,Feng L,Li X.Ionizing radiation-inducible microRNA-21 induces angiogenesis by directly targeting PTEN.Asian Pac J Cancer Prev2019;20:1587-93 PMCID:PMC6857897

[73] Kalajahi HG,Amini M.Therapeutic effect of microRNA-21 on differentially expressed hub genes in gastric cancer based on systems biology.Sci Rep2023;13:21906 PMCID:PMC10713559

[74] Meng L,Wu J.Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.Cell Death Dis2024;15:3 PMCID:PMC10766988

[75] Shibru B,Fricke S.Detection of immune checkpoint receptors - a current challenge in clinical flow cytometry.Front Immunol2021;12:694055 PMCID:PMC8281132

[76] Kipkeeva F,Korotaeva A.The features of immune checkpoint gene regulation by microRNA in cancer.Int J Mol Sci2022;23:9324 PMCID:PMC9409052

[77] Martinez-Usatorre A,Carmona SJ.MicroRNA-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in melanoma.Cancer Immunol Res2019;7:1013-24

[78] Li D,Wang X.Cathelicidin, an antimicrobial peptide produced by macrophages, promotes colon cancer by activating the Wnt/β-catenin pathway.Oncotarget2015;6:2939-50 PMCID:PMC4413629

[79] Noman MZ,Abdou A.The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.Oncoimmunology2017;6:e1263412 PMCID:PMC5283623

[80] Kim MK, Suh C, Lee DH, et al.; Korean Multiple Myeloma Working Party. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients.Ann Oncol2011;22:411-6

[81] Nam DY.Identifying microRNAs associated with tumor immunotherapy response using an interpretable machine learning model.Sci Rep2024;14:6172 PMCID:PMC10940311

[82] Li J,Ai J.Machine learning in the prediction of immunotherapy response and prognosis of melanoma: a systematic review and meta-analysis.Front Immunol2024;15:1281940 PMCID:PMC11148209

[83] Hücker SM,Werno C.Single-cell microRNA sequencing method comparison and application to cell lines and circulating lung tumor cells.Nat Commun2021;12:4316 PMCID:PMC8280203

[84] Chiang NJ,Bai LY.Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study.NPJ Precis Oncol2025;9:307 PMCID:PMC12398617

[85] Nguyen MT,Li AL.MiRNA as a Modulator Of Immunotherapy And Immune Response In Melanoma.Biomolecules2021;11:1648 PMCID:PMC8615556

[86] Motti ML,Di Carluccio G,Carriero MV.MicroRNAs as key players in melanoma cell resistance to MAPK and immune checkpoint inhibitors.Int J Mol Sci2020;21:4544 PMCID:PMC7352536

[87] Yadav R,Yap KC.The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer.Cell Death Discov2024;10:414 PMCID:PMC11439964

[88] García-Giménez JL,Ortega AL.MiRNAs related to immune checkpoint inhibitor response: a systematic review.Int J Mol Sci2024;25:1737 PMCID:PMC10855819

[89] Yu D,Han G.The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.Cell Commun Signal2019;17:173 PMCID:PMC6935121

[90] Zhang L,Bonome T.Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.Proc Natl Acad Sci U S A2008;105:7004-9 PMCID:PMC2383982

[91] Li K,Zhou Y.An integrated approach to reveal miRNAs’ impacts on the functional consequence of copy number alterations in cancer.Sci Rep2015;5:11567 PMCID:PMC4477324

[92] Seviour EG,Lu Y.Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.Oncogene2016;35:691-701 PMCID:PMC4522411

[93] Seo Y,Kim N,Park JB.Development of a miRNA-controlled dual-sensing system and its application for targeting miR-21 signaling in tumorigenesis.Exp Mol Med2020;52:1989-2004 PMCID:PMC8080684

[94] Okumura S,Komatsu Y.Stable duplex-linked antisense targeting miR-148a inhibits breast cancer cell proliferation.Sci Rep2021;11:11467 PMCID:PMC8169724

[95] Sun L,Ye Y.Smart nanoparticles for cancer therapy.Signal Transduct Target Ther2023;8:418 PMCID:PMC10622502

[96] Fattore L,Di Martile M.Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance.Oncogene2023;42:293-307 PMCID:PMC9684877

[97] Marei HE,Pozzoli G.Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.Cancer Cell Int2023;23:64 PMCID:PMC10088229

[98] Vischioni C,De Chiara M.MiRNAs copy number variations repertoire as hallmark indicator of cancer species predisposition.Genes2022;13:1046 PMCID:PMC9223155